Source BioScience News

The Company is delighted to announce the launch of its new, enhanced website encompassing its entire spectrum of life science activities - www.lifesciences.sourcebioscience.com

Dr Gordon Blackshields, Senior Bioinformatician for Source BioScience will be presenting at the Illumina Sequencing Seminar in Manchester, Crown Plaza Hotel on Tuesday 7th September 2010. The title of his talk is "Application of Illumina Sequencing to the Genetics of Human Cancers". Representatives from Source BioScience will be happy to discuss your project requirements and how we could be of assistance to you. Please contact us at lifesciences.services@sourcebioscience.com

An agenda for the Seminar is attached.

The Company today announced its interim results for the six months ended 30 June 2010.

Source BioScience will announce its half yearly report for the six months ended 30 June 2010 on Tuesday 24 August 2010.

The Company has experienced good trading conditions in Q2, in line with those previously reported in May for Q1, and the Group continues to trade in line with management expectations.

Dr Jackie Rodgers, Head of Pharma Biotech Business Development, Worldwide, for Source BioScience, the Nottingham, UK based healthcare and biotechnology company, will be attending the 2010 Molecular Diagnostics Meeting in Boston, 21-23 June, where she will be presenting two posters: “Evaluating gene expression in FFPE breast cancer tissues using DASL” and “Sequence polymorphism indentification within the TP53 gene of cancer samples: A comparison of traditional Sanger-and next-generation sequencing as tools for supporting drug development”.

Dr Rodgers would be pleased to hear from companies wishing to discuss how Source BioScience could be of assistance in these areas, and can be contacted via email – jackie.rodgers@sourcebioscience.com or enquiries@sourcebioscience.com.

Dr Cliff Murray, Head of Research and Development for Source BioScience, the Nottingham, UK based healthcare and biotechnology company, will be attending the ASCO Annual Meeting to discuss partnering opportunities with pharmaceutical and biotech companies. The expertise offered by Source BioScience supports clinical trials with contract research services, assisting biomarker discovery and validation, pharmacogenomics and biobanking. Dr Murray will also be evaluating opportunities for in-licensing and developing reference laboratory services for novel diagnostic, prognostic and predictive tests.

Dr Murray would be pleased to hear from companies wishing to discuss how Source BioScience could be of assistance in this area of expertise. Please contact him via email - cliff.murray@sourcebioscience.com, or enquiries@sourcebioscience.com.

The Company today provides its Interim Management Statement as required by the UK Listing Authority's Disclosure and Transparency Rules, relating to the period from 1 January 2010 to 18 May 2010.

The Company is pleased to announce the addition of a companion diagnostic testing service for stomach cancer patients in the UK to its portfolio of services.

Source BioScience plc confirms that its 2010 Annnual General Meeting will be held at the Company's registered offices, 1 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX at 10.30am on 10 June 2010. Formal notice of this meeting has been posted to shareholders together with a copy of the Annual Report and Accounts 2009, a copy of which can be downloaded from the website.

Senior members of the Heathcare division of Source BioScience will be attending the 17th International Congress of Cytology in Edinburgh, between 16 and 20 May 2010, and look forward to networking with a wide range of specialists in the field of cytology, a rapidly developing area of pathology.

Source BioScience offers a comprehensive solution for cervical screening, through the BD Surepath™ liquid based cytology (LBC) and BD FocalPoint™ Guided Screening Imaging systems and would be pleased to discuss how their expertise in these areas could benefit clinicians and oncologists.

For further information, please visit the team at Stand 13 or contact healthcare@sourcebioscience.com.

The Company is pleased to announce the addition of Synvolux Therapeutics BV to its supplier portfolio. Synvolux Therapeutics BV, based in Groningen, the Netherlands, specialises in the development of transfection reagents and protocols which guarantee a high cell transfection efficacy combined with minimal cell death.

Their specific delivery technology (SAINT™) is based on a set of proprietary, entirely synthetic lipid structures which, coupled with optimised transfection protocols provides great benefits to the customer and adds depth to our range of transfection products.

For further details please contact Dr Tracey Long, Product Manager for Source BioScience's Life Science division – tracey.long@sourcebioscience.com.

Using its in-house expertise in genomics, Source BioScience has developed and validated pyrosequencing assays for the major activiating mutations of the NRAS and BRAF genes, suitable for use in archival (FFPE) material. The NRAS test is the first of its kind commercially available in the UK.

Regrettably, owing to the travel disruption caused by volcanic ash air contamination, Dr Cliff Murray, Head of Research & Development for Source BioScience, the Nottingham, UK based healthcare and biotechnology company, has been unable to attend the American Association for Cancer Research conference in Washington, USA, April 17th - 21st. The Company would have been presenting a poster entitled "Evaluating gene expression in FFPE breast cancer tissues using DASL®".

Dr Murray would be pleased to hear from companies wishing to discuss how Source BioScience could be of assistance in this area of expertise. Please contact him via email - cliff.murray@sourcebioscience.com, or enquiries@sourcebioscience.com.

The Board of Source BioScience plc today announces its unaudited results for the year ended 31 December 2009.

Source BioScience plc expects to announce its preliminary results for the year ended 31 December 2009 on 24 March 2010.

There will be a presentation for analysts at 10.00am on 24 March at the offices of Bishopsgate Communications, 5-11 Worship Street, London, EC2A 2BH. Analysts wishing to attend should contact Gemma O'Hara at Bishopsgate Communications (0207 562 3350) before 12.00 on 22 March.

The results presentation will be made available on the Company's website, www.sourcebioscience.com, after commencement of the meeting.

The Company is pleased to announce the opening of its new DNA sequencing laboratory based in Dublin, Ireland.

Source BioScience Healthcare, a leading provider of histopathology, diagnostic tests and cytology services to the NHS and private hospitals, is pleased to announce the addition of a new Gastric HER2 test to its portfolio of tests. This follows the recent approval by the European Medicines Agency of the use of Herceptin in the treatment of metastatic gastric cancer. Source BioScience is the only laboratory in the UK offering this test.

For more information please go to GASTRIC HER2 test or contact our Business Development Team on 0115 79739056.

The Board of Source BioScience plc is pleased to announce the appointment with immediate effect of Singer Capital Markets Limited as the Company's Financial Advisor and Joint Stockbroker.

Dr Jackie Rodgers, Head of Business Development, Pharma Biotech Worldwide for Source BioScience, the Nottingham, UK based healthcare and biotechnology company, will be attending the Molecular Medicine Triconference in San Francisco from the 1st - 5th February. The Company is presenting a poster entitled "A comparison of methods for retrieval of DNA and RNA from FFPE tissues".

Dr Rodgers would be pleased to meet with companies wishing to discuss how Source BioScience could be of assistance in this area of expertise. Please contact her via email - jackie.rodgers@sourcebioscience.com.

The Company is pleased to announce the purchase of a further two Illumina Genome Analyzer IIx™ platforms to significantly enhance its DNA sequencing service.